Capital Advisors Inc. OK Invests $220,000 in OPKO Health, Inc. (NASDAQ:OPK)

Capital Advisors Inc. OK acquired a new stake in OPKO Health, Inc. (NASDAQ:OPK) during the 4th quarter, HoldingsChannel reports. The firm acquired 150,000 shares of the biotechnology company’s stock, valued at approximately $220,000.

Several other institutional investors and hedge funds have also bought and sold shares of OPK. FMR LLC raised its stake in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 11,089 shares during the period. Orion Portfolio Solutions LLC bought a new stake in OPKO Health in the 3rd quarter valued at about $45,000. Private Advisor Group LLC raised its stake in OPKO Health by 242.7% in the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock valued at $53,000 after acquiring an additional 25,000 shares during the period. World Investment Advisors LLC purchased a new stake in OPKO Health during the third quarter valued at about $61,000. Finally, Ground Swell Capital LLC bought a new position in OPKO Health during the third quarter worth about $63,000. 64.63% of the stock is owned by institutional investors.

OPKO Health Trading Up 1.2 %

Shares of OPKO Health stock opened at $1.64 on Thursday. The company’s 50-day moving average price is $1.53 and its 200-day moving average price is $1.53. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -8.63 and a beta of 1.63. OPKO Health, Inc. has a 12-month low of $0.86 and a 12-month high of $1.76. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30.

Insiders Place Their Bets

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 47,537 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was bought at an average price of $1.47 per share, with a total value of $69,879.39. Following the completion of the acquisition, the chief executive officer now owns 213,234,014 shares of the company’s stock, valued at $313,454,000.58. This trade represents a 0.02 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders have bought 1,621,609 shares of company stock worth $2,472,710 in the last three months. 47.26% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on OPK shares. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research report on Wednesday, January 8th. StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 15th. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Friday, November 8th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.